Polyrizon Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $20.8M
- Price
- $8.58
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.21%
- Volume
- 5.3K
About
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Quick stats
Shares outstanding2.4M
Computed float—
Float / sharesUnknown
Cash runway (months)30.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001893645
AI Summary
AI-generated1/25
minorbullishclinical trial
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
Polyrizon completed enrollment and randomization of all 120 planned participants in its U.S. multicenter clinical study of NASARIX, its investigational nasal hydrogel for protection against airborne allergens.
The randomized, controlled study compares NASARIX against a saline control in adults with allergic rhinitis across five U.S. clinical sites; 144 individuals were screened to hit the target.
Data review and analysis will follow completion of treatment and follow-up periods; the company expects to advance toward a clinical data readout.